Quantisnow Logo
Dashboard

SEC Form 25-NSE filed by Medicenna Therapeutics Corp.

$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MDNA alert in real time by email
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 333-238905
Issuer: Medicenna Therapeutics Corp.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 2 Bloor St. W, 7th Floor
Toronto ONTARIO, CANADA M4W 3E2 CA
Telephone number: (416) 648-5555
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Shares
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2023-11-20 By Aravind Menon Hearings Advisor
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $MDNA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MDNA

DatePrice TargetRatingAnalyst
More analyst ratings

$MDNA
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

    TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTC:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. The highlights of the data set will be presented by: Dr Steven Brem, M.D., Medical Director, Centre for Precisio

    $MDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

    MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation and evaluation portion of the ABILITY-1 Study including deep ongoing partial responses with 100% reduction of target lesions in one pancreatic and 70% reduction of target lesion in one melanoma cancer patientMDNA11 also showed durable stable disease in 3 melanoma patients for at least 5 months to 18 months with concomitant shrinkage of tumor size following failure with check-point inhibitor therapiesMDNA11 is generally well tolerated with no dose-limiting toxicities or vascular leak syndrome reported in any of the dose escalation cohortsMedicenna believes that these data reaffirm the differentiated and

    $MDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

    Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymes IL-13Rα2 is overexpressed by some of the most immunologically "cold" tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patients TORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Com

    $MDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MDNA
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MDNA
 SEC Filings

See more

$MDNA
 Leadership Updates

Live Leadership Updates

See more

  • Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

    TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna's clinical programs. "We are thrilled to welcome Dr. Gardner as Medicenna's new CMO and member of our management team. Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies for cancer and other diseases from the earliest stages of development through regulatory approvals," said Fahar Merc

    $MDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Medicenna Announces Results of Annual and Special Meeting of Shareholders

    TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") ((NASDAQ, TSX:MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company's annual and special meeting of shareholders held today, September 28, 2023 (the "Meeting"). Medicenna is pleased to announce that all of the nominees listed in the management information circular dated August 9, 2023 (the "Circular"), were elected as directors. Each director was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote

    $MDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

    Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

    $EDIT
    $MDNA
    $TNGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$MDNA
 Financials

Live finance-specific insights

See more

  • Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

    TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors. Shareholders and financial analysts are invited to join the live audio webcast either by phone or through the webcast link. Both options to connect to the webcast are described on Medicenna's website: https://ir.medicenna.com/news-and-events/events-and-presentations The webcast will b

    $MDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

    Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicitiesMDNA11 clinical update scheduled for August 9; conference call to discuss data from cohorts five and six, recommended dose for monotherapy expansion and details on Phase 2 trial design$29.6 million in cash and cash equivalents as of June 30, 2023 provides expected runway through the completion of the ABILITY study and through calendar Q3 2024 TORONTO and HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy compa

    $MDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights

    Phase 1/2 ABILITY study advancing to sixth dose escalation cohort following positive review of safety and pharmacodynamic data from fifth cohort Initial PK/PD data from ABILITY's fifth dose escalation cohort expected alongside updated anti-tumor data in calendar Q1 2023$36.2 million in cash and cash equivalents at December 31, 2022 provides expected runway through the completion of the ABILITY study and through calendar Q2 2024 Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immunotherapy company, today announced it

    $MDNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MDNA
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more